Ab­b­Vie turns its back on Har­poon’s BC­MA-tar­get­ing mul­ti­ple myelo­ma drug

Ab­b­Vie is walk­ing away from an ex­clu­sive op­tion for Har­poon’s BC­MA-tar­get­ing T cell en­gager for mul­ti­ple myelo­ma, leav­ing the Cal­i­for­nia com­pa­ny to ad­vance the as­set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.